These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 34456293)

  • 1. Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data.
    Nie RC; Chen GM; Wang Y; Yuan SQ; Zhou J; Duan JL; Liu WW; Chen S; Cai MY; Li YF
    J Immunother; 2021 Nov-Dec 01; 44(9):371-375. PubMed ID: 34456293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
    Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
    Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Zhang T; Li S; Chang J; Qin Y; Li C
    BMC Cancer; 2023 Oct; 23(1):1023. PubMed ID: 37872469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
    Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
    Front Immunol; 2022; 13():968729. PubMed ID: 35967438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis.
    Tian BW; Han CL; Wang HC; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Yang LS; Tan SY; Dong ZR; Yan YC; Wang DX; Li T
    Clin Exp Metastasis; 2023 Aug; 40(4):255-287. PubMed ID: 37308706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
    Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
    JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between body mass index and survival outcomes for cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    An Y; Wu Z; Wang N; Yang Z; Li Y; Xu B; Sun M
    J Transl Med; 2020 Jun; 18(1):235. PubMed ID: 32532255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
    Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of Efficacy of Immune Checkpoint Inhibitors in Cancer Patients Older Than 75?
    Wu Q; Luo S; Xie X
    J Immunother; 2022 Sep; 45(7):307-320. PubMed ID: 35674663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients.
    Basak EA; van der Meer JWM; Hurkmans DP; Schreurs MWJ; Oomen-de Hoop E; van der Veldt AAM; Bins S; Joosse A; Koolen SLW; Debets R; Peeters RP; Aerts JGJV; Mathijssen RHJ; Medici M
    Thyroid; 2020 Jul; 30(7):966-973. PubMed ID: 32151195
    [No Abstract]   [Full Text] [Related]  

  • 13. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis.
    Takenaka Y; Oya R; Takemoto N; Inohara H
    J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1122-1135. PubMed ID: 34337889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between body mass index, dosing strategy, and efficacy of immune checkpoint inhibitors.
    Ahmed M; von Itzstein MS; Sheffield T; Khan S; Fattah F; Park JY; Popat V; Saltarski JM; Gloria-McCutchen Y; Hsiehchen D; Ostmeyer J; Khan SA; Sultana N; Xie Y; Li QZ; Wakeland EK; Gerber DE
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34127546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
    Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
    Front Oncol; 2022; 12():976224. PubMed ID: 36185176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of the pretreatment lung immune prognostic index with survival outcomes in advanced gastric cancer patients treated with immune checkpoint inhibitors.
    Hou B; Wang P; Liu T; Chen S; Li T; Zhang S; Tao H; Li X; Hu Y
    Clin Res Hepatol Gastroenterol; 2021 Sep; 45(5):101748. PubMed ID: 34182184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.
    Cortellini A; Ricciuti B; Vaz VR; Soldato D; Alessi JV; Dall'Olio FG; Banna GL; Muthuramalingam S; Chan S; Majem M; Piedra A; Lamberti G; Andrini E; Addeo A; Friedlaender A; Facchinetti F; Gorría T; Mezquita L; Hoton D; Valerie L; Nana FA; Artingstall J; Comins C; Di Maio M; Caglio A; Cave J; McKenzie H; Newsom-Davis T; Evans JS; Tiseo M; D'Alessio A; Fulgenzi CAM; Besse B; Awad MM; Pinato DJ
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35173031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.